Seres Therapeutics (NASDAQ:MCRB) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.03, Fidelity Earnings reports. Seres Therapeutics had a negative net margin of 264.31% and a negative return on equity of 256.24%. The business had revenue of $9.06 million for the quarter, compared to analysts’ expectations of $23.43 million.
Shares of Seres Therapeutics stock traded down $0.48 on Friday, hitting $8.40. The stock had a trading volume of 155,488 shares, compared to its average volume of 100,299. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.76 and a current ratio of 2.76. Seres Therapeutics has a one year low of $5.64 and a one year high of $11.35. The stock has a market capitalization of $330.04 million, a price-to-earnings ratio of -3.80 and a beta of 0.61.
In other news, insider John G. Aunins sold 42,837 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $7.64, for a total value of $327,274.68. Following the transaction, the insider now owns 146,648 shares in the company, valued at $1,120,390.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John G. Aunins sold 14,279 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $5.94, for a total transaction of $84,817.26. Following the completion of the transaction, the insider now owns 103,811 shares in the company, valued at approximately $616,637.34. The disclosure for this sale can be found here. Insiders sold 69,634 shares of company stock worth $526,006 in the last 90 days. Company insiders own 37.10% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Seres Therapeutics in the second quarter worth approximately $117,000. Northern Trust Corp grew its holdings in shares of Seres Therapeutics by 6.0% in the second quarter. Northern Trust Corp now owns 246,310 shares of the biotechnology company’s stock worth $2,118,000 after purchasing an additional 14,021 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Seres Therapeutics by 18.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock worth $1,009,000 after purchasing an additional 18,562 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Seres Therapeutics by 175.0% in the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 23,222 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Seres Therapeutics by 0.4% in the third quarter. FMR LLC now owns 6,119,349 shares of the biotechnology company’s stock worth $46,446,000 after purchasing an additional 23,749 shares during the last quarter. Hedge funds and other institutional investors own 77.92% of the company’s stock.
MCRB has been the topic of a number of recent research reports. BidaskClub cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th. ValuEngine cut shares of Seres Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 30th. Zacks Investment Research upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 1st. Bank of America cut shares of Seres Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Friday, August 3rd. Finally, Chardan Capital initiated coverage on shares of Seres Therapeutics in a research report on Monday, October 22nd. They set a “buy” rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Seres Therapeutics currently has an average rating of “Hold” and an average price target of $13.81.
COPYRIGHT VIOLATION WARNING: “Seres Therapeutics (MCRB) Announces Earnings Results” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/11/10/seres-therapeutics-mcrb-announces-earnings-results.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.